About Us

Scientific Advisory Board

Stephen E. Epstein, M.D.

Director, Translational and Vascular Biology Research, MedStar Heart Institute, MedStar Washington Hospital Center
Clinical Professor of Medicine, Georgetown University

After graduating Summa Cum Laude from Columbia College, Dr. Epstein completed his medical training at Cornell University Medical College and interned at New York Hospital, New York, NY. Prior to joining MedStar Health, Dr. Epstein served for over 30 years as Chief of the Cardiology Branch of the NHLBI at the National Institutes of Health in Bethesda, MD.

Dr. Epstein oversees translational research conducted within the MedStar Heart Institute. With more than 500 publications in peer-reviewed medical journals, Dr. Epstein is a recognized international authority on angiogenesis and on the application of stem cell strategies for cardiovascular therapeutics, including the use of nanoparticle technology as a drug delivery platform for targeting the delivery of stem cell-derived factors and other molecules to relevant cardiovascular tissues. He has also studied possible genetic polymorphisms and circulating biomarkers as indicators that a given patient is at risk of plaque rupture. He and his team have explored how aging leads to collateral dysfunction.

These research accomplishments led to Dr. Epstein serving on two important National Heart, Lung, and Blood Institute (NHLBI) committees: Vice-Chairman of the Data Safety Management Board (DSMB) for Programs of Excellence in Gene and Cell Therapy for the Heart, Lung, and Blood Institute, and Chairman of the DSMB for Specialized Centers for Clinically Oriented Research in Cardiac Dysfunction and Disease.

In addition to his research and leadership responsibilities, Dr. Epstein serves as Clinical Professor of Medicine at the Georgetown University School of Medicine. He is a Fellow of the American Heart Association, a member of the Association of American Physicians, and an Honorary Fellow of the American College of Chest Physicians. Dr. Epstein is the recipient of the Distinguished WELCOME Lecturer award, was selected for the prestigious Pfizer Visiting Professor Program, and is a frequent invited lecturer and keynote speaker at national and international medical conferences.

Javed Butler, M.D., MPH, FACC, FAHA

Chief of the Cardiology Division, Stony Brook Heart Institute

Dr. Javed Butler is the chief of the Cardiology Division at the Stony Brook Heart Institute, a position he accepted after serving eight years as a director of Heart Failure Research at Emory Health and an Emory University professor of cardiology. Before that, he was the director for the Heart and Heart-Lung Transplant programs at Vanderbilt University. He also has done special cardiac imaging training at Boston’s Massachusetts General Hospital. He is on the Editorial Board for the Journal of the American College of Cardiology, Journal of Cardiac Failure, American Heart Journal and Congestive Heart Failure. He served on the American College of Cardiology Committee on Heart Failure and Transplantation. Dr. Butler’s research focuses primarily on the disease progression, outcomes, and prognosis determination in patients with heart failure, with special emphasis on patients undergoing cardiac transplantation and left ventricular assist device placement. He is board certified in cardiology, internal medicine, and nuclear cardiology. Currently he serves as the deputy chief science advisor for the American Heart Association. After completing his M.D. from Aga Khan University in Karachi, Pakistan, Dr. Butler did his residency and chief residency at Yale University, earned his M.P.H. from Harvard University and garnered a cardiology fellowship from Vanderbilt University.

Mihai Gheorghiade, M.D., FACC

Professor of Medicine and Surgery, Associate Director, Director of Experimental Therapeutics, Center for Cardiovascular Innovation at the Northwestern University Feinberg School of Medicine
Adjunct Professor, Duke University

Dr. Mihai Gheorghiade is a professor of medicine and surgery, associate director and director of Experimental Therapeutics at the Center for Cardiovascular Innovation, Department of Medicine, at Northwestern University’s Feinberg School of Medicine and Northwestern Memorial Hospital. He is also an adjunct professor of medicine at Duke University. Before that he was chief of the Cardiac Intensive Care Unit at the Henry Ford Hospital in Detroit, as well as associate professor of Clinical Medicine at the University of Michigan. His first post as chief of cardiology was at the Salem VA Medical Center. He also served as associate professor of medicine at the University of Virginia. Dr. Gheorghiade is a member of many national and international committees and serves on the editorial board and has been guest editor of many journals, including the “American Heart Journal,” “The American Journal of Cardiology,” “The Journal of the American College of Cardiology,” “Circulation: Heart Failure and The American Journal of Medicine and Heart Failure Clinics.” In addition, he chaired the steering committee for many heart-failure clinical-research trials including OPTIME-HF, ACTIV-HF, IMPACT, PRESERVD, HORIZON, COMPOSE, ASTRONAUT, RENO-DEFEND, IMPROVE-HF Bridge and Stresscopin trials. He co-chairs the international EVEREST and ECLIPSE trials, and was a member of the Steering Committee of RADIANCE, FIRST, CARS, RITZ 4 and EPHESUS trials. He is the author of over 600 publications and over 300 original presentations at national and international meetings. He was recently co-editor of two comprehensive textbooks on acute heart failure syndromes and has written several chapters in many textbooks including “Kelley’s Textbook of Internal Medicine,” and “Heart Failure: A Companion to Braunwald’s Heart Disease,” and, most recently, authored a chapter on acute heart failure syndromes in the ninth edition of “Braunwald’s Heart Disease.” At present, his major goal is to improve the post-discharge outcomes in patients hospitalized with acute heart failure syndromes. He earned his M.D., magna cum laude from the University of Rome and did his training in internal medicine and cardiology at Brown University.

Arshed Ali Quyyumi, M.D., FRCP, FACC

Co-Director, Emory Clinical Cardiovascular Research Institute (ECCRI)
Professor of Cardiology, Emory University

Dr. Arshed A. Quyyumi is co-director of the Emory Clinical Cardiovascular Research Institute (ECCRI) and an Emory University professor of cardiology. He has been involved in clinical translational research in cardiovascular diseases for more than 25 years. Since 2005, Dr. Quyyumi has been awarded more than $9 million in research funding. He serves on the editorial boards of several national journals, is a member on several Scientific Advisory Boards and is a reviewer for the NIH-NHLBI Study Sections. He has authored more than 180 peer-reviewed publications and has been an invited speaker and session chair at numerous National and International scientific meetings and conferences. Dr. Quyyumi’s research focus includes vascular biology, angiogenesis, progenitor cell biology, mechanisms of myocardial ischemia, and the role of genetic and environmental risks on vascular disease. He has carried out more than 50 NIH, industry-funded or investigator-initiated projects, including numerous clinical trials. He earned his B.S. in pharmacology and M.D. from the University of London. He completed his residency at Guy’s and Royal Free Hospitals in London, and he received cardiology fellowships at London’s National Heart Hospital, Boston’s Massachusetts General Hospital and the National Institutes of Health. After completion of his residency and fellowship, he served as senior investigator, director of the Cardiac Catheterization Laboratory and other positions in the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI) Cardiology Branch.

Robert L. Wilensky, M.D.

Director, Interventional Cardiology, University of Pennsylvania School of Medicine
Professor of Medicine, University of Pennsylvania

Dr. Robert L. Wilensky is professor of medicine and director of Interventional Cardiology Research at the University of Pennsylvania. He divides his time between the cardiac catheterization laboratories and the translational animal laboratory. His research interests include acute coronary syndromes, diabetic vasculopathy, and diagnosis and treatment of vulnerable coronary lesions. He has been an active organizer of and participant in many international cardiology symposia, including the Vulnerable Plaque Summits at the Cardiovascular Revascularization Therapies (CRT) meetings and the Transcatheter Therapeutics (TCT) meetings. He is a fellow of the American College of Cardiology and the American Heart Association. In addition, he is the author or co-author of more than 140 papers and holds three U.S. patents. Dr. Wilensky received his M.D. with distinction from the University of Amsterdam. His internship and residency in internal medicine was obtained at the Georgetown University Medical Center/VAMC in Washington, D.C. His fellowship in cardiology was at the Krannert Institute of Cardiology at Indiana University, where he became chief fellow and, later, assistant professor of medicine.